These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 17456926)
1. Effect of tazarotene on ichthyosiform erythroderma of Tay's syndrome. Varghese VS; Rai R; Sundaram SV; Prabhu KS; Srinivas CR Indian J Dermatol Venereol Leprol; 2007; 73(2):126-7. PubMed ID: 17456926 [No Abstract] [Full Text] [Related]
2. Erythrokeratoderma variabilis successfully treated with topical tazarotene. Yoo S; Simzar S; Han K; Takahashi S; Cotliar R Pediatr Dermatol; 2006; 23(4):382-5. PubMed ID: 16918639 [TBL] [Abstract][Full Text] [Related]
3. Ichthyosis bullosa of Siemens: response to topical tazarotene. Rajiv S; Rakhesh SV Indian J Dermatol Venereol Leprol; 2006; 72(1):43-6. PubMed ID: 16481710 [TBL] [Abstract][Full Text] [Related]
4. Bullous congenital ichthyosiform erythroderma: safe and effective topical treatment with calcipotriol ointment in a child. Bogenrieder T; Landthaler M; Stolz W Acta Derm Venereol; 2003; 83(1):52-4. PubMed ID: 12636025 [No Abstract] [Full Text] [Related]
5. Treatment of ichthyosiform diseases with topically applied tazarotene: risk of systemic absorption. Nguyen V; Cunningham BB; Eichenfield LF; Alió AB; Buka RL J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S123-5. PubMed ID: 17938025 [No Abstract] [Full Text] [Related]
6. A case of mosaic-type bullous congenital ichthyosiform erythroderma successfully treated with topical maxacalcitol, a vitamin D3 analogue. Umekoji A; Fukai K; Ishii M Clin Exp Dermatol; 2008 Jul; 33(4):501-2. PubMed ID: 18498407 [No Abstract] [Full Text] [Related]
7. [Medication of the month. Tazarotene 0.05%-0.1% (Zorac)]. Henno A; Hua MT; de la Brassinne M Rev Med Liege; 2003 Nov; 58(11):706-8. PubMed ID: 14748200 [TBL] [Abstract][Full Text] [Related]
15. Treatment of occupational koilonychia with tazarotene gel. Hagman JH; Ginebri A; Mordenti C; De Simoni I; Chimenti S Acta Derm Venereol; 2003; 83(4):296-7. PubMed ID: 12926806 [No Abstract] [Full Text] [Related]
16. Successful topical adapalene treatment for the facial lesions of an adolescent case of epidermolytic ichthyosis. Ogawa M; Akiyama M J Am Acad Dermatol; 2014 Sep; 71(3):e103-5. PubMed ID: 25128122 [No Abstract] [Full Text] [Related]
17. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene. Cotellessa C; Cuevas-Covarrubias SA; Valeri P; Fargnoli MC; Peris K Acta Derm Venereol; 2005; 85(4):346-8. PubMed ID: 16191859 [No Abstract] [Full Text] [Related]
18. Tazarotene foam, 0.1%, for the treatment of acne. Smith JA; Narahari S; Hill D; Feldman SR Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170 [TBL] [Abstract][Full Text] [Related]
19. Successful treatment of Favre-Racouchot disease with 0.05% tazarotene gel. Rallis E; Karanikola E; Verros C Arch Dermatol; 2007 Jun; 143(6):810-2. PubMed ID: 17576962 [No Abstract] [Full Text] [Related]
20. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Tanghetti EA; Cutis; 2000 Dec; 66(6 Suppl):4-11. PubMed ID: 11147088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]